Web of Science: 2 citations, Scopus: 2 citations, Google Scholar: citations,
Pazopanib : Evidence review and clinical practice in the management of advanced renal cell carcinoma
Méndez-Vidal, María José (Hospital Reina Sofía, Córdoba)
Molina, Áurea (Complejo Hospitalario Universitario A Coruña)
Anido, Urbano (Complejo Hospitalario Universitario de Santiago)
Chirivella, Isabel (Hospital Clínico Universitario de Valencia)
Etxaniz, Olatz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fernández-Parra, Eva (Hospital Nuestra Señora del Valme)
Guix, Marta (Hospital del Mar)
Hernández, Carolina (Hospital Universitario Nuestra Señora de Candelaria)
Lambea, Julio (Hospital Clínico Universitario Lozano Blesa)
Montesa, Álvaro (Hospital Regional de Málaga)
Pinto, Álvaro (Hospital la Paz)
Ros, Silverio (Hospital Universitario Virgen de la Arrixaca)
Gallardo, Enrique (Parc Taulí Hospital Universitari)
Universitat Autònoma de Barcelona

Date: 2018
Abstract: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. A non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer. The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all. This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles.
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès.
Document: article ; recerca ; publishedVersion
Subject: Antineoplastic agents ; Carcinoma, renal cell ; Kidney neoplasms ; Protein kinase inhibitors ; Quality of life ; Pazopanib
Published in: BMC Pharmacology & Toxicology, Vol. 19 (november 2018) , ISSN 2050-6511

PMID: 30477570
DOI: 10.1186/s40360-018-0264-8

12 p, 710.3 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles

 Record created 2019-08-12, last modified 2019-09-30

   Favorit i Compartir